Chronic Verubecestat treatment suppresses amyloid accumulation in advanced aged Tg2576-APPswe mice without inducing microhemorrhage

Manuscript Number: 

17-0056R1

Author(s): 
Xia Chen, Thomas Forest, Daniel J. Holder, Lynn A. Hyde, Matthew E. Kennedy, Eric M. Parker, Marie Sondey, Cyrille Sur, Stephanie Villarreal, Fuqiang Zhao

Disclosures

Xia Chen

  • Nothing to Disclose

Thomas Forest

  • Equity:
    Restricted Stock Shares of Merck & Co.
    Sponsors:
    Senior Principal Scientist at Merck Research Laboratories

Daniel J. Holder

  • Equity:
    ~$150K in Merck stock, the company at which I am employed
    Sponsors:
    Biostatistician at Merck

Lynn A. Hyde

  • Equity:
    I own some Merck/MSD stock
    Sponsors:
    I am employed by Merck/MSD

Matthew E. Kennedy

  • Equity:
    I am an employee of Merck &Co. and own company stock.
    Sponsors:
    I am an employee of Merck &Co.

Eric M. Parker

  • Consulting Fees:
    Paid consultant of Kallyope, Inc. and The New York Stem Cell Foundation
    Equity:
    Own stock in Merck and Kallyope

Marie Sondey

  • Nothing to Disclose

Cyrille Sur

  • Equity:
    Merck Restricted Share Unit
    Sponsors:
    Full time Merck and Co employee. Distinguished Scientist, Translational Biomarkers Dept

Stephanie Villarreal

  • Equity:
    Merck
    Sponsors:
    Scientist at Merck

Fuqiang Zhao

  • Equity:
    BP PLC SPONSORED ADR (BP): 585 BOEING CO (BA): 125 CHEVRON CORP NEW COM (CVX): 109 COSTCO WHOLESALE CORP (COST): 277 FEDERAL NATL MTG ASSN (FNMA): 200 GENERAL ELECTRIC CO (GE): 200 MERCK & CO INC NEW COM (MRK): 1420. NVIDIA CORP (NVDA): 26 ALPHABET INC CAP STK CL A (GOOGL); 14 EXXON MOBIL CORP (XOM): 70 WELLS FARGO CO NEW COM (WFC): 135